Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000905148-25-000909·BridgeBio Pharma, Inc.
Schedule 13D ownership disclosure
BRIDGEBIO PHARMA INC
Common Stock, par value $0.001 per share · CUSIP: 10806X102
Event date: 2025-01-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LPReported CIK 0001103804
Shares: 22,055,375 · Class: 11.7%
- VIKING GLOBAL PERFORMANCE LLCReported CIK 0001132625
Shares: 487,901 · Class: 0.3%
- Viking Global Equities Master Ltd.Reported CIK 0001759530
Shares: 487,901 · Class: 0.3%
- Viking Long Fund GP LLCReported CIK 0001621607
Shares: 194,184 · Class: 0.1%
- Viking Long Fund Master Ltd.Reported CIK 0001621596
Shares: 194,184 · Class: 0.1%
- Viking Global Opportunities Parent GP LLCReported CIK 0001886738
Shares: 21,373,290 · Class: 11.3%
- Viking Global Opportunities GP LLCReported CIK 0001629476
Shares: 21,373,290 · Class: 11.3%
- Viking Global Opportunities Portfolio GP LLCReported CIK 0001629472
Shares: 21,373,290 · Class: 11.3%
- Viking Global Opportunities Illiquid Investments Sub-Master LPReported CIK 0001629482
Shares: 21,373,290 · Class: 11.3%
- HALVORSEN OLE ANDREASReported CIK 0001133006
Shares: 22,055,375 · Class: 11.7%
- Ott David C.Reported CIK 0001621842
Shares: 22,055,375 · Class: 11.7%
- Shabet Rose SharonReported CIK 0001711393
Shares: 22,055,375 · Class: 11.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-000909
- Form type
- SCHEDULE 13D/A
- Filer
- BridgeBio Pharma, Inc.
- CIK
- CIK 1743881
- Filed
- Mar 12, 2025
- Reporting period
- Jan 31, 2025
- Description
- Schedule 13D beneficial ownership